NEUROCRINE BIOSCIENCES INC (NBIX)

130.25 2.49 (1.95%)

As of 2026-02-17 17:18:05 EST

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Traded asNasdaq: NBIX
ISINUS64125C1099
CIK0000914475
LEI549300FECER0XBN49756
EIN330525145
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOKyle Gano
Employees1,350
Fiscal Year End1231
Address6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
Phone(858) 617-7600
Websitehttp://neurocrine.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
NBIXNEUROCRINE BIOSCIENCES INC2026-02-17 17:18:05130.252.491.95
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
NBIX0000914475NEUROCRINE BIOSCIENCES INCUS64125C1099549300FECER0XBN49756330525145Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE6027 EDGEWOOD BEND COURTSAN DIEGOCA92130UNITED STATESUS(858) 617-76006027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 921306027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130—Biotechnology1992Kyle Gano1,350http://neurocrine.com9,520,000,000100,100,000100,363,463Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).2026-02-12 15:57:08
This is a preview of the latest data. Subscribe to access the full data.
NBIX Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
NBIX Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20259,520,000,000-980,000,000-9.3333100,363,463659,9360.6619
202410,500,000,0002,600,000,00032.911499,703,527196,0370.197
20237,900,000,000-197,146,859-2.434899,507,4902,919,5793.0227
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Jude Onyia, Ph.D.Chief Scientific Officer2023638,250351,0382,625,124—233,7807,223,216
Eiry W. RobertsChief Medical Officer2023660,348399,5112,125,112—63,8525,873,847
Kevin C. Gorman, Ph.D.Chief Executive Officer2023946,0001,040,6007,021,386—64,03615,750,812
Matthew C. AbernethyChief Financial Officer2023646,061355,3351,812,563—56,3876,057,882
Eiry W. RobertsChief Medical Officer2022631,912345,1822,075,144—57,9865,735,281
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20241,800
20231,400
2020845
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue2,860,500,0002,355,300,0001,887,100,000
Cost Of Revenue52,100,00034,000,00039,700,000
Gross Profit———
Research And Development Expenses1,015,700,000731,100,000565,000,000
General And Administrative Expenses1,156,200,0001,007,200,000887,600,000
Operating Expenses2,241,400,0001,784,800,0001,636,200,000
Operating Income619,100,000570,500,000250,900,000
Net Income478,600,000341,300,000249,700,000
Earnings Per Share Basic4.813.42.56
Earnings Per Share Diluted4.673.292.47
Weighted Average Shares Outstanding Basic99,500,000100,400,00097,700,000
Weighted Average Shares Outstanding Diluted102,500,000103,700,000101,000,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents713,000,000233,000,000251,100,000
Marketable Securities Current767,400,000843,100,000780,500,000
Accounts Receivable686,800,000479,100,000439,300,000
Inventories69,000,00057,400,00038,300,000
Non Trade Receivables———
Other Assets Current115,800,000112,100,00097,800,000
Total Assets Current2,522,700,0001,724,700,0001,607,000,000
Marketable Securities Non Current1,063,000,000739,500,000687,500,000
Property Plant And Equipment89,800,00082,600,00070,800,000
Other Assets Non Current59,500,00015,500,00049,600,000
Total Assets Non Current2,108,800,0001,994,000,0001,644,400,000
Total Assets4,631,500,0003,718,700,0003,251,400,000
Accounts Payable674,300,000461,600,000448,800,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current69,100,00046,100,00035,900,000
Total Liabilities Current743,400,000507,700,000654,800,000
Long Term Debt———
Other Liabilities Non Current219,700,000166,200,000106,300,000
Total Liabilities Non Current635,000,000621,300,000364,600,000
Total Liabilities1,378,400,0001,129,000,0001,019,400,000
Common Stock100,000100,000100,000
Retained Earnings447,700,00029,200,000-157,100,000
Accumulated Other Comprehensive Income13,100,0005,800,0007,000,000
Total Shareholders Equity3,253,100,0002,589,700,0002,232,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization26,000,00023,500,00017,800,000
Share Based Compensation Expense217,900,000195,500,000194,300,000
Other Non Cash Income Expense———
Change In Accounts Receivable210,500,00039,800,00089,300,000
Change In Inventories15,300,00019,100,000-5,400,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable160,200,00029,000,00064,300,000
Change In Other Liabilities44,400,000-10,700,000-47,800,000
Cash From Operating Activities782,700,000595,400,000389,900,000
Purchases Of Marketable Securities1,319,800,0001,056,100,0001,379,900,000
Sales Of Marketable Securities1,089,400,000967,500,000972,400,000
Acquisition Of Property Plant And Equipment34,000,00038,200,00028,300,000
Acquisition Of Business—00
Other Investing Activities———
Cash From Investing Activities-264,400,000-126,800,000-467,100,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock129,400,000122,100,00065,300,000
Repurchase Of Common Stock167,700,000300,000,000—
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities-38,300,000-486,700,00065,300,000
Change In Cash480,000,000-18,100,000-11,600,000
Cash At End Of Period713,000,000233,000,000251,100,000
Income Taxes Paid81,400,000217,500,00051,500,000
Interest Paid01,600,0003,800,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share4.813.42.56
Price To Earnings Ratio29.486540.147151.4688
Earnings Growth Rate41.470632.812559.0062
Price Earnings To Growth Ratio0.7111.22350.8723
Book Value Per Share32.694525.793822.8454
Price To Book Ratio4.3385.2925.7675
Ebitda586,000,000582,300,000323,600,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures33,200,00035,300,00030,000,000
Free Cash Flow749,500,000560,100,000359,900,000
Return On Equity0.14710.13180.1119
One Year Beta0.85050.54520.4241
Three Year Beta0.67550.50670.5433
Five Year Beta0.62040.65120.699
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Cooke JulieChief Human Resources Officer2026-02-131,510A30,395
Cooke JulieChief Human Resources Officer2026-02-13815D29,580
Cooke JulieChief Human Resources Officer2026-02-139,968A39,548
Cooke JulieChief Human Resources Officer2026-02-135,378D34,170
Cooke JulieChief Human Resources Officer2026-02-131,401D2,802
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Lisa McClain2025-08-13MI09Sale (Partial)2025-06-17Spouse$1,001 - $15,000
Lisa McClain2025-08-13MI09Purchase2025-06-11Spouse$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Pathstone Holdings, LLC2025-12-311,691,60611,927141.83
IEQ CAPITAL, LLC2025-12-31105,679,358745,113141.83
Vontobel Holding Ltd.2025-12-31386,0612,722141.8299
Boston Partners2025-12-317,725,47054,472141.8246
Caitong International Asset Management Co., Ltd2025-12-3139,429278141.8309
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
BAIRD FUNDS INC2025-12-31Institutional ClassBSGIX21,2773,017,716.913.0393
BAIRD FUNDS INC2025-12-31Investor ClassBSGSX21,2773,017,716.913.0393
EMPOWER FUNDS, INC.2025-12-31Institutional ClassMXMSX10,5341,494,037.20.5278
EMPOWER FUNDS, INC.2025-12-31Investor ClassMXMTX10,5341,494,037.20.5278
EMPOWER FUNDS, INC.2025-12-31Institutional ClassMXNZX46,1576,546,447.450.4382
This is a preview of the latest data. Subscribe to access the full data.